PSI-7977 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C Infection
Links shared publicly online about this topic.
- 951total visits
PSI-7977 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C Infection
View full resource at medicalnewstoday.com
Tags: Liver Condition, Hepatitis, Hepatitis C, Infection, Drug, FDA
Most Recently Shared on August 13, 2010 at 2:01 pm By:
PSI-7977 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C Infection http://mnt.to/3Hkx
Also Shared By:
Fast Track Designation for PSI-938 for Chronic Hepatitis C Infection - MPR
empr.com — “Pharmasset has received fast track designation from the FDA for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection.” View full resource at empr.com
Most Recently Shared on August 24, 2011 at 2:35 pm By:
Fast Track Designation for PSI-938 for Chronic Hepatitis C Infection http://ow.ly/6bxqd #hepatitis
PSI-7977 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C Infection - QualityPoint Technologies
qualitypointtech.net — “Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-7977 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1. ” View full resource at qualitypointtech.net
Most Recently Shared on August 13, 2010 at 12:45 pm By:
PSI-7977 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C Infection: Pharmass... http://bit.ly/8Yu2BO
Advertisement
MNT Clinical Trials
@mnt_clinical
PSI-7977 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C Infection http://mnt.to/3Hkx #clinicaltrials
1 year ago...